NeuroOne Medical Technologies Corporation develops medical technology for surgical diagnosis and treatment of neurological disorders. The company’s platform centers on thin-film electrode technology used in recording, monitoring, mapping, ablation and brain stimulation applications, including Evo Cortical, Evo sEEG and the OneRF Ablation System.
NeuroOne news commonly covers FDA 510(k) clearances, product applications for epilepsy, facial pain and other neurosurgical uses, patent activity around neural probe and electrode technologies, financial results, capital raises, commercial orders, investor conferences and management updates. Coverage also reflects the company’s efforts to extend the OneRF platform into additional ablation, stimulation and drug-delivery applications.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) announced a telephone replay of its investor conference call will be available until April 11, 2022. The call discussed the company's recent disclosures, including clarification on its 510(k) clearance request for the Evo® sEEG Electrode for short-term use. CEO Dave Rosa, along with biocompatibility expert Dr. William Wustenberg, addressed public questions during the call. The device is already cleared for use of less than 24 hours. For further details, visit www.n1mtc.com.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) will host a conference call on March 29, 2022, at 10:00 am ET, to discuss recent disclosures related to its 510(k) clearance request for the Evo® sEEG Electrode. This device is already cleared for temporary use of less than 24 hours and seeks approval for less than 30 days. Investors and interested parties can join via the provided dial-in numbers or access the live webcast. The call aims to clarify the recent 8-K filing and answer participant questions.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) announced the approval of an equity award as part of its 2021 Inducement Plan, effective March 1, 2022. This award was granted to a new employee, providing them the option to purchase 10,000 shares at $1.95 per share, the closing price on the granting date. The award will vest 25% after one year and the rest in monthly installments over three years, contingent on continued employment. This move aligns with Nasdaq's regulations requiring public disclosure of non-stockholder approved equity awards.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) will showcase its innovative technology at two investor conferences in March 2022. The Oppenheimer 32nd Annual Virtual Healthcare Conference is scheduled for March 16, 2022, at 1:20 p.m. ET, while the 34th Annual ROTH Conference will take place from March 13-15, 2022, in Laguna Niguel, California. CEO Dave Rosa will discuss the company's Evo® Cortical Electrodes aimed at improving care for neurological disorders. The firm is also exploring advancements in artificial intelligence and machine learning.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) announced successful completion of initial bench top testing on its thin film electrode technology, showing potential for chronic stimulation use over approximately 5 years. The tests confirmed the electrodes' durability and performance at higher stimulation levels. CEO Dave Rosa highlighted the opportunity for expansion into treatment areas like epilepsy and chronic back pain. The market potential for related technologies is estimated at over $10 billion. The company is advancing its electrode technologies for various neurological disorders.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) announced its Q1 fiscal 2022 results, reporting product revenue of $34,000, down from $71,000 in Q1 2021. Collaboration revenue also decreased from $22,000 to $6,000. Operating expenses rose to $2.8 million, with a net loss of $2.8 million, compared to $2 million the previous year. The company strengthened its financial position through a public offering, generating $13.35 million. Key developments include FDA clearance requests for its Evo sEEG Electrode, with expected commercial readiness and milestone payments from Zimmer Biomet.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) announced successful pre-clinical long-term testing of its thin film electrode technology, showing reliability in recording electrical activity for over 5 years. The accelerated aging tests confirmed the electrodes' ability to withstand environmental challenges, a key issue in neurotechnology. CEO Dave Rosa highlighted the potential for these electrodes in treating conditions like epilepsy and Parkinson's disease, and the company aims to explore research market opportunities and strategic partnerships in this field. NeuroOne's therapeutic electrode technologies target over $10 billion in addressable markets.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) will host a conference call on February 14, 2022, at 4:30 PM Eastern Time to discuss its first-quarter fiscal results for 2022, which ended on December 31, 2021. This call is part of the company’s commitment to improving surgical care for patients with neurological disorders. Interested parties can access the call via toll-free numbers or the provided webcast link.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) has appointed Chad Wilhelmy as Vice President of Quality Control and Regulatory Affairs. With 20 years of experience in the medical device industry, Wilhelmy aims to enhance the company's quality systems and regulatory foundations. As part of his employment, he received an option to purchase 50,000 shares at an exercise price of $1.95 per share. CEO Dave Rosa expressed confidence in Wilhelmy's experience to support the company's growth, focusing on improving surgical care for neurological disorders.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) is featured on The Medical Alley Podcast, highlighting their innovations in neurological care. CEO Dave Rosa discusses the company's development of high-definition film electrodes aimed at treating conditions like epilepsy. The podcast aims to enhance public awareness about NeuroOne's commitment to improving surgical options and outcomes for patients with neurological disorders.